The latest price target for TRACON Pharma (OTCQB:TCON) was reported by HC Wainwright & Co. on July 1, 2024. The analyst firm set a price target for $0.00 expecting TCON to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for TRACON Pharma (OTCQB:TCON) was provided by HC Wainwright & Co., and TRACON Pharma downgraded their neutral rating.

There is no last upgrade for TRACON Pharma

The last downgrade for TRACON Pharmaceuticals Inc happened on July 1, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for TRACON Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TRACON Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TRACON Pharma was filed on July 1, 2024 so you should expect the next rating to be made available sometime around July 1, 2025.

While ratings are subjective and will change, the latest TRACON Pharma (TCON) rating was a downgraded with a price target of $0.00 to $0.00. The current price TRACON Pharma (TCON) is trading at is $0.03, which is out of the analyst’s predicted range.